Case 2: Antiretroviral Regimens for Initial Therapy - Antiretroviral Rx

Case-Based Modules
Initial Evaluation
Dermatologic Manifestations
Oral Manifestations
OIs: Prophylaxis
OIs: Treatment
Antiretroviral Rx
Antiretroviral Rx: Resistance
Antiretroviral Rx: Adverse Effects
Drug-Drug Interactions
Postexposure Prophylaxis
Perinatal Transmission
Special Populations
Prevention for Positives
Challenging Unknowns
Interactive Tutorials
This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.

Home
About This Site
Free CME
AETC NRC
Resources
Feedback
Site Map
Authors

Question | Discussion | References | CME Credit

Case 2: Antiretroviral Regimens

You answered:

	Stavudine (Zerit) plus lamivudine (Epivir) plus lopinavir-ritonavir (Kaletra) is considered a preferred regimen.

This answer is incorrect. This combination of drugs would not be considered a preferred regimen because stavudine is no longer a preferred drug. The removal of stavudine from the preferred group of drugs resulted from numerous studies that have shown a high rate of long-term adverse effects caused by stavudine.

Choose another answer:

	Zidovudine-lamivudine (Combivir) plus efavirenz (Sustiva) is considered a preferred regimen.
	Tenofovir-emtricitabine (Truvada) plus ritonavir (Norvir) plus darunavir (Prezista) is considered a preferred regimen.
	Abacavir (Ziagen) plus tenofovir (Viread) plus lamivudine (Epivir) is considered an alternative regimen.

[Back to Case 2 Question | Go to Correct Answer]